Mer­ck makes a $773M bet on TGFβ, ac­quir­ing a three-year-old biotech

When check­point in­hibitors work, they can per­form won­ders. But for many can­cer pa­tients, in-built or ac­quired re­sis­tance to these im­munother­a­pies im­pedes their ef­fi­ca­cy. Mer­ck, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER